Morbidity and mortality of hyperthermic intraperitoneal chemoperfusion

Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) is a treatment option for peritoneal surface malignancy. Despite the survival benefits, this treatment was previously associated with a high morbidity and mortality rates, and the perception of the poor periop...

Full description

Saved in:
Bibliographic Details
Published in:Chirurg 2013-11, Vol.84 (11), p.957
Main Authors: Pelz, J O W, Germer, C-T
Format: Article
Language:ger
Subjects:
Chemotherapy, Cancer, Regional Perfusion - adverse effects
Combined Modality Therapy
Cooperative Behavior
Hyperthermia, Induced - adverse effects
Infusions, Parenteral - adverse effects
Interdisciplinary Communication
Neoplasm Staging
Patient Selection
Peritoneal Neoplasms - mortality
Peritoneal Neoplasms - pathology
Peritoneal Neoplasms - therapy
Peritoneum - surgery
Postoperative Complications - mortality
Registries
Survival Rate
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) is a treatment option for peritoneal surface malignancy. Despite the survival benefits, this treatment was previously associated with a high morbidity and mortality rates, and the perception of the poor perioperative outcomes associated with this regimen remains. Careful patient selection with an optimal level of postoperative care must be advocated to avoid undesirable complications of this treatment.However, for this treatment to be accepted as standard of care, teams undertaking this treatment strategy must aim to minimize morbidity and mortality by learning from the experience of established centers and using the "global learning curve". The HIPEC Registry and accreditation of centers will improve the quality of the treatment.
ISSN:1433-0385
DOI:10.1007/s00104-013-2513-0